lidERA
The first oral SERD to reduce recurrence after surgery, by about 30%, compared with today's hormone pills.
Presented SABCS December 2025: ~30% reduction in invasive disease-free survival events versus standard endocrine therapy, consistent across menopausal status (ASCO 2026 subgroup: 35% pre-, 26% post-menopausal). Regulatory submission planned. If approved, the first change to adjuvant endocrine backbone since aromatase inhibitors.
- The treated group had about 30 percent lower chance of the event at any given time (hazard ratio 0.7).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- 30% reduction in iDFS events vs standard ET
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Adjuvant ER+/HER2- early breast cancer (medium-high risk): giredestrant vs standard endocrine therapy for 5 years. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
4,200 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Invasive disease-free survivalprimary | Giredestrant | — | 30% reduction in iDFS events vs standard ET | 0.7 | — | link |
| Standard endocrine therapy | — | — |
Pages like this
not linked directly; found by shared links- TrialpersevERA
Shares Giredestrant, HR-positive / HER2-negative breast cancer.
- TrialevERA
Shares Giredestrant, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- TermOral SERD
Shares Giredestrant, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- InstitutionBarbara Ann Karmanos Cancer Institute
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- IdeaIntercepting late recurrence with ctDNA surveillance and oral SERDs
Shares Giredestrant, HR-positive / HER2-negative breast cancer.
- TrialMONALEESA-2
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- ProductFluoroestradiol F-18 (FES PET)
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- ProductGoserelin / leuprolide (ovarian function suppression)
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.